2020 年第 3 期 第 15 卷

吉非替尼对表皮生长因子受体突变型非小细胞肺癌的临床疗效观察及药物敏感性分析

Efficacy and sensitivity of epidermal growth factor receptor tyrosine kinase inhibitor in treatment of epidermal growth factor receptor-mutant non-small cell lung cancer

作者：黄良龙1张利诚1金晓辉1邱雨宽2

英文作者：

单位：1中国人民武装警察部队海警总队医院呼吸科，浙江省嘉兴市314000；2中国人民武装警察部队海警总队医院肿瘤科，浙江省嘉兴市314000

英文单位：

关键词：非小细胞肺癌；表皮生长因子受体酪氨酸激酶抑制剂；敏感性

英文关键词：

• 摘要：

• 【摘要】目的    探究表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗表皮生长因子受体(EGFR)突变型非小细胞肺癌(NSCLC)的临床效果及敏感性。方法    选择2016年4月至2019年1月中国人民武装警察部队海警总队医院诊治的100例NSCLC患者为研究对象。根据患者是否存在EGFR基因突变分为突变组(45例)和非突变组(55例)。所有患者采用吉非替尼治疗。观察2组患者临床疗效、肺癌细胞增殖抑制率、迁移及侵袭能力。结果    突变组临床有效率明显高于非突变组［82.2%（37/45）比36.4%（20/55）］，差异有统计学意义（P＜0.001）。突变组肺癌细胞药物培养后1、2、3 d细胞增殖抑制率明显高于非突变组［（48.0±1.5）%比（25.9±1.7）%、（71.2±1.7）%比（30.2±1.3）%、（84.4±1.4）%比（34.6±1.6）%］，且用药后的细胞迁移能力和侵袭能力明显低于非突变组［（146±29）个比（201±29）个、（15±6）个比（26±4）个］，差异均有统计学意义(均P＜0.05)。结论    EGFR-TKI药物治疗EGFR突变型NSCLC患者有明显临床效果与敏感性。

  
  

• 【Abstract】Objective    To investigate the efficacy and sensitivity of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) in treatment of epidermal growth factor receptor(EGFR)-mutant non-small cell lung cancer(NSCLC). Methods    A total of 100 patients with NSCLC admitted to Marine Police General Hospital, the Chinese People′s Armed Police Force from April 2016 to January 2019 were divided into EGFR gene mutation group(n＝45) and non-mutation group(n＝55). All patients were treated with gefitinib. Clinical efficacy, lung cancer cell proliferation inhibition rate, migration and invasion ability were analyzed. Results    Clinical effective rate in the mutation group was significantly higher than that in the non-mutation group［82.2%（37/45） vs 36.4%（20/55）］（P＜0.001）. After co-culture with EGFR-TKI, the 1, 2, 3 d proliferation inhibition rates in the mutation group were significantly higher than those in the non-mutation group［（48.0±1.5）% vs （25.9±1.7）%, （71.2±1.7）% vs （30.2±1.3）%, （84.4±1.4）% vs （34.6±1.6）%］; cell migration and invasion ability in the mutation group were significantly lower than those in the non-mutation group［（146±29） vs （201±29）, （15±6） vs （26±4）］(all P＜0.05). Conclusion    EGFR-TKI shows good clinical efficacy and sensitivity in treating EGFR-mutant NSCLC.